Upneeq fda approval date?

When did Upneeq (oxymetazoline ophthalmic solution) get FDA approval?

Upneeq received FDA approval on September 14, 2016. [1]

Was that approval for the same indication Upneeq is used for today?

Upneeq’s approval was for the temporary improvement of visual function in patients with acquired blepharoptosis (ptosis) who have sufficient levator function. [1]

What is Upneeq, and how does it work?

Upneeq is an oxymetazoline hydrochloride ophthalmic solution. It works by stimulating alpha-adrenergic receptors in the eye’s tissues, which helps lift the eyelid in appropriate patients. [1]

Source

1. DrugPatentWatch.com – Upneeq FDA approval and patent information